Home›Carbidopa Tablets

Carbidopa Tablets

Also known as: Carbidopa

Aromatic Amino Acid Decarboxylation InhibitorDOPA Decarboxylase Inhibitors

Route: Oral

11 interactions on record

Carbidopa Tablets has 11 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Monoamine Oxidase Inhibitors (Type A Or B), Rasagiline, Selegiline. Patients taking Carbidopa Tablets should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 11
Contraindicated: 3
Moderate: 8

Contraindicated (3)

Carbidopa Tablets + Monoamine Oxidase Inhibitors (Type A Or B)— Contraindicated per label contraindications section.
Carbidopa Tablets + Rasagiline— Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.
Carbidopa Tablets + Selegiline— Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.

Moderate (8)

Carbidopa Tablets + Butyrophenones— Dopamine D2 receptor antagonists may reduce therapeutic effects of levodopa; patients should be carefully observed for l…
Carbidopa Tablets + Iron Salts— Should be coadministered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailabilit…
Carbidopa Tablets + Isoniazid— May reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.
Carbidopa Tablets + Metoclopramide— May adversely affect disease control by dopamine receptor antagonistic properties, despite increasing gastric emptying a…
Carbidopa Tablets + Papaverine— Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of…
Carbidopa Tablets + Phenothiazines— Dopamine D2 receptor antagonists may reduce therapeutic effects of levodopa; patients should be carefully observed for l…
Carbidopa Tablets + Phenytoin— Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of…
Carbidopa Tablets + Risperidone— Dopamine D2 receptor antagonist may reduce therapeutic effects of levodopa; patients should be carefully observed for lo…

Carbidopa Tablets + Monoamine Oxidase Inhibitors (Type A Or B)⛔Contraindicated

Contraindicated per label contraindications section.

Carbidopa Tablets + Rasagiline⛔Contraindicated

Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.

Carbidopa Tablets + Selegiline⛔Contraindicated

Concomitant therapy may be associated with severe orthostatic hypotension; contraindicated per label.

Carbidopa Tablets + Butyrophenones🟡Moderate

Dopamine D2 receptor antagonists may reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Iron Salts🟡Moderate

Should be coadministered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailability.

Carbidopa Tablets + Isoniazid🟡Moderate

May reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Metoclopramide🟡Moderate

May adversely affect disease control by dopamine receptor antagonistic properties, despite increasing gastric emptying and levodopa bioavailability.

Carbidopa Tablets + Papaverine🟡Moderate

Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Phenothiazines🟡Moderate

Dopamine D2 receptor antagonists may reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Phenytoin🟡Moderate

Beneficial effects of levodopa in Parkinson's disease may be reversed; patients should be carefully observed for loss of therapeutic response.

Carbidopa Tablets + Risperidone🟡Moderate

Dopamine D2 receptor antagonist may reduce therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.